Edwards Lifesciences Corp (EW)

Official site

HEALTHCARE • MEDICAL DEVICES • NYSE

$102.14

+1.31 (+1.30%)

Market Cap: $58.11B

Last updated: Nov 06, 2026 at 4:38 PM ET

Earnings

Performance (10Y)

Beat Rate

83%(33/40)

Avg Surprise

+7.72%

Streak

3 Q

Upcoming Estimates

Period ending Dec 31, 2026

EPS Consensus$0.79

Range$0.75 - $0.84

29 analysts

Revenue Consensus

$1.8B

Range$1.7B - $1.9B

28 analysts

Last 12 of 40 reported quarters and 1 upcoming estimate

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$0.79	$0.75 - $0.84	-	-	29	-	-
Sep 30, 2026Sep 26 Reported Nov 4, 2026Reported Nov 4	$0.80	$0.73	$0.72 - $0.77	+9.59%	Beat	24	2 15 30d	+19.4%
Jun 30, 2026Jun 26 Reported Jul 23, 2026Reported Jul 23	$0.78	$0.73	$0.73 - $0.76	+6.85%	Beat	22	1 1 30d	+16.4%
Mar 31, 2026Mar 26 Reported Apr 23, 2026Reported Apr 23	$0.78	$0.73	$0.71 - $0.75	+6.85%	Beat	24	13 2 30d	+21.9%
Dec 31, 2025Dec 25 Reported Feb 10, 2026Reported Feb 10	$0.58	$0.62	$0.60 - $0.65	-6.39%	Miss	27	6 2 30d	-1.7%
Sep 30, 2025Sep 25 Reported Oct 30, 2025Reported Oct 30	$0.67	$0.59	$0.57 - $0.62	+13.56%	Beat	25	6 1 30d	+0.0%
Jun 30, 2025Jun 25 Reported Jul 24, 2025Reported Jul 24	$0.67	$0.62	$0.60 - $0.65	+8.06%	Beat	26	1 0 30d	-4.3%
Mar 31, 2025Mar 25 Reported Apr 23, 2025Reported Apr 23	$0.64	$0.60	$0.57 - $0.64	+6.67%	Beat	26	0 1 30d	-3.0%
Dec 31, 2024Dec 24 Reported Feb 11, 2025Reported Feb 11	$0.59	$0.55	$0.53 - $0.64	+6.38%	Beat	27	1 1 30d	-7.8%
Sep 30, 2024Sep 24 Reported Oct 24, 2024Reported Oct 24	$0.67	$0.59	$0.54 - $0.70	+13.56%	Beat	26	1 1 30d	+13.6%
Jun 30, 2024Jun 24 Reported Jul 24, 2024Reported Jul 24	$0.70	$0.69	$0.67 - $0.71	+1.45%	Beat	26	2 1 30d	+6.1%
Mar 31, 2024Mar 24 Reported Apr 25, 2024Reported Apr 25	$0.66	$0.64	$0.63 - $0.66	+3.13%	Beat	25	0 1 30d	+6.5%
Dec 31, 2023Dec 23 Reported Feb 6, 2024Reported Feb 6	$0.64	$0.64	$0.62 - $0.67	+0.00%	Beat	25	1 0 30d	+0.0%

Key Metrics

Valuation
P/E Ratio	34.74	EV/EBITDA	39.72x
Price/FCF	41.33x	FCF Yield	2.42%
Profitability
Profit Margin	15.40%	Operating Margin	29.80%
ROE	9.18%	ROIC	7.47%
Financial Health
Debt/Equity	0.06x	Interest Coverage	55.12x
Current Ratio	4.60x	Quick Ratio	3.86x
Trading Statistics
Beta	0.83	Avg Volume	4.71M
52-Week High	$104.17	52-Week Low	$74.66

Technical Indicators Dashboard

Moving Averages

SMA 10$95.04

SMA 20$91.31

SMA 50$88.92

SMA 200$85.77

EMA 10$95.96

EMA 20$92.94

EMA 50$90.18

EMA 200$86.54

MACD

Line: 3.19Signal: 1.88Hist: 1.31

ADX

ADX: 25.8+DI: 32.2-DI: 12.0

Aroon & PSAR

Aroon Up96.0

Aroon Down16.0

PSAR$89.49

Bollinger Bands

Upper Band$101.16

Lower Band$81.47

%B Position2156%(Upper)

Band Width1.05

RSI (14-Day)

Overbought

76.8

Momentum Oscillators

Stoch %K87.6

Stoch %D88.0

Williams %R-11.9

ROC (10d)14.7%

Momentum13.06

CCI (20d)174.2

MFI (14d)67.4

Volatility Measures

ATR (14d)$3.03(3.0%)

StdDev (20d)4.92

Hist Vol25.8%(Moderate)

Volume Flow

VWAP$100.94

OBV140.1M

AD Line72.4M

CMF (20d)0.250

Volume Metrics

Avg Vol (20d)4.7M

Vol Ratio1.1x

VWMA (20d)$92.84

Pivot Points

R3$109.13

R2$106.65

R1$103.73

Pivot Point$101.25

S1$98.34

S2$95.86

S3$92.94

Advanced Oscillators

TSI35.07

Ultimate Osc63.0

KST87.18

Financial Data

Quarter	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023
Total Revenue	$1.72B	$1.74B	$1.65B	$1.57B	$1.55B	$1.53B	$1.41B	$1.39B	$1.35B	$1.37B	$1.33B	$1.01B
Cost of Revenue	$369.20M	$392.40M	$362.60M	$343.00M	$345.20M	$344.40M	$301.60M	$292.20M	$262.90M	$275.50M	$286.90M	$141.40M
Gross Profit	$1.35B	$1.35B	$1.29B	$1.23B	$1.21B	$1.19B	$1.11B	$1.09B	$1.09B	$1.09B	$1.04B	$870.10M

Operating Expenses	$1.05B	$835.40M	$808.40M	$1.03B	$900.80M	$776.60M	$716.30M	$781.00M	$740.90M	$727.40M	$694.00M	$579.00M
R&D	$281.40M	$278.90M	$263.30M	$267.70M	$280.70M	$276.20M	$254.60M	$271.10M	$253.40M	$271.80M	$256.70M	$215.20M
SG&A	$560.90M	$561.20M	$522.20M	$602.90M	$514.60M	$502.00M	$465.70M	$491.90M	$421.40M	$447.50M	$428.40M	$353.90M
Operating Income	$299.10M	$513.20M	$477.60M	$151.10M	$307.10M	$411.20M	$394.80M	$312.60M	$350.60M	$366.50M	$349.00M	$291.10M

Interest Income	$36.50M	$30.00M	$33.50M	$56.30M	$38.60M	$37.40M	$36.50M	$64.00M	$24.30M	$15.50M	$16.50M	$0
Interest Expense	$0	$0	$18.60M	$60.70M	$0	$11.00M	$0	$0	$0	$0	$0	$50.40M
Income Before Tax	$363.20M	$519.80M	$459.00M	$90.40M	$348.40M	$400.20M	$433.90M	$390.10M	$402.80M	$384.00M	$371.20M	$311.10M
Income Tax Expense	$61.80M	$278.40M	$78.30M	$26.20M	$56.10M	$64.30M	$70.30M	$45.10M	$40.70M	$20.00M	$46.30M	$20.70M

Net Income	$301.40M	$241.40M	$380.70M	$91.20M	$290.30M	$331.50M	$356.40M	$384.30M	$3.07B	$365.00M	$351.00M	$369.70M

EBITDA	$371.60M	$532.50M	$466.40M	$50.10M	$349.00M	$400.90M	$434.00M	$388.50M	$413.00M	$408.10M	$393.20M	$331.00M
EBIT	$326.70M	$489.80M	$425.50M	$7.40M	$309.80M	$362.80M	$397.40M	$345.90M	$378.50M	$368.50M	$354.70M	$294.30M

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

Why TransMedics Stock is a Buy for Long-Term Investors

TransMedics is replacing a 60-year-old organ-transport method with its FDA-approved OCS platform, which keeps hearts, lungs, and livers alive and functioning during transit — a massive step-change in reliability and outc Business model now prints cash...

Glenn Ford

•

Nov 14, 202511/14/25

•

308

medical-technology, healthcare-innovation, organ-transplant, growth-stocks

Also mentions:

ISRGSYKMDTABTEW

Government Contracts

Gov Obligations (TTM)

$27.76M

Gov Obligations / Revenue

0.4%

Obligations YoY

-1.3%

Active Awards

641

New Awards (TTM)

620

Avg Remaining Term

5.4 mo

Top agency: Department of Veterans Affairs at 97.1% of trailing twelve month obligations across 2 agencies

Recent Awards

Award ID	Agency	Obligated	Start	End	Description
36C24726P0498	Department of Veterans AffairsDepartment of Veterans Affairs	$402000	Apr 15, 2026	May 29, 2026	HEMODYNAMIC MONITORING SYSTEM
36C25726N0365	Department of Veterans AffairsDepartment of Veterans Affairs	$374000	Jun 1, 2026	May 31, 2027	SAPIEN 3 RESILIA HEART VALVE
36C25526K0170	Department of Veterans AffairsDepartment of Veterans Affairs	$306000	Jan 1, 2026	Mar 31, 2026	EXPRESS REPORT: TAVR HEART VALVES
36C25526K0096	Department of Veterans AffairsDepartment of Veterans Affairs	$266000	Oct 1, 2025	Dec 31, 2025	EXPRESS REPORT: STL HEART VALVES
HT001426PE034	Department of DefenseDefense Health Agency	$238000	Jan 13, 2026	Jan 30, 2026	SAPIEN3 ULTRA RESILIA KITS FOR WALTER REED NATIONAL MILITARY MEDICAL CENTER.
HT001425PE045	Department of DefenseDefense Health Agency	$238000	Sep 12, 2025	Dec 12, 2025	TRANSCATHETER HEART VALVE REPLACEMENT SYSTEMS
36C26126P1000	Department of Veterans AffairsDepartment of Veterans Affairs	$231200	Jul 29, 2026	Aug 29, 2026	HEART VALVE
HT001426PE069	Department of DefenseDefense Health Agency	$204000	Mar 3, 2026	Mar 31, 2026	SAPIEN 3 ULTRA RESILIA HEART VALVES SIZES 26 MILLIMETER AND 29 MILLIMETER.
36C26126P0688	Department of Veterans AffairsDepartment of Veterans Affairs	$204000	Apr 29, 2026	May 29, 2026	PROSTHETICS - HEART IMPLANTS
36C26126P0330	Department of Veterans AffairsDepartment of Veterans Affairs	$204000	Jan 13, 2026	Feb 13, 2026	PROSTHETICS - TAVR

Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

News

Edwards Lifesciences (EW) Could Be 21% Undervalued After Earnings Guidance And Trial Data

Edwards Lifesciences (EW) has seen a significant shift in sentiment, with its stock up 16.6% in the last month and 18.2% year-to-date, following positive third-quarter results, increased full-year sales guidance...

Simply Wall St•Nov 6, 2026 4:28 PM ET11/6/26•Somewhat-Bullish

Cardinal Health Raises FY2027 Guidance Despite 28% Profit Drop In Medical Products Segment

Cardinal Health increased its fiscal 2027 non-GAAP EPS guidance to $12.80–$13, following a rise in first-quarter non-GAAP EPS to $3.26...

insights.citeline.com•Nov 6, 2026 11:33 AM ET11/6/26•Somewhat-Bullish

Laureate unit in Peru buys UCAL for ~$35M to expand Lima capacity

Laureate Education's Peruvian subsidiary, Universidad Peruana de Ciencias Aplicadas (UPC), acquired Universidad de Ciencias y Artes de América Latina (UCAL) for approximately $35 million on November 5...

StreetInsider•Nov 5, 2026 4:12 PM ET11/5/26•Neutral

Edwards Lifesciences (EW) Stock Looks Fully Priced On Cash Flow

Edwards Lifesciences (EW) has seen a strong 50% share gain over the past three years. However, a Discounted Cash Flow (DCF) analysis suggests the current stock price of US$99 is significantly above its intrinsic value...

Simply Wall St•Nov 5, 2026 3:19 PM ET11/5/26•Somewhat-Bearish

Marea Therapeutics to present at major November investor conferences on new cardioendocrine drug developments

Marea Therapeutics, a subsidiary of Lisata Therapeutics, will present at major investor conferences in November...

Pluang•Nov 5, 2026 10:30 AM ET11/5/26•Somewhat-Bullish

EW Valuation and Fair Value

P/E: 34.7x
Forward P/E: 29.3x
EV/EBITDA: 39.7x
P/FCF: 41.3x
PEG: 2.1x
P/B: 5.4x

See GNG's fair value

EW Profitability: Margins, ROIC and FCF

Gross margin: 78.0%
Operating margin: 29.8%
Net margin: 15.4%
ROIC: 7.5%
ROE: 9.2%
FCF margin: 21.3%
FCF yield: 2.4%

EW Competitors

Company	Ticker
Becton Dickinson and Company	BDX
Natera Inc	NTRA
argenx NV ADR	ARGX
IDEXX Laboratories Inc	IDXX
Cardinal Health Inc	CAH
Veeva Systems Inc Class A	VEEV
Boston Scientific Corp	BSX
Humana Inc	HUM

Sector: Healthcare

EW Analyst Ratings

Consensus: Buy
Analysts: 30
Strong Buy: 5
Buy: 18
Hold: 7
Sell: 0
Strong Sell: 0

EW Bull Case vs Bear Case

Bull case

EW converts 21.3% of revenue into free cash flow.
EW beat EPS estimates in 87.5% of its last 8 reported quarters.
EW grew quarterly revenue 13.6% year over year.

EW Earnings: Beat Rate and Next Report

Beat rate: 7 of 8 quarters (87.5%)
Average surprise: 6.4%
EPS estimate (fiscal period ending Dec 31, 2026): $0.79

EW Earnings Date

EW reports Feb 8, 2027, after the close. The date is estimated.

EW Earnings Call

The latest EW earnings call transcript on file is labeled 2026Q3.

Read the 2026Q3 transcript

EW ETF Holders

GNG tracks 43 ETFs that hold EW. The largest weights:

iShares U.S. Medical Devices ETF (IHI), 4.49% of the fund
BlackRock Health Sciences Trust (BME), 2.25% of the fund
Invesco S&P 500 Equal Weight Health Care ETF (RSPH), 1.63% of the fund
State Street SPDR S&P Health Care Equipment ETF (XHE), 1.63% of the fund
BLCR, 1.56% of the fund

Open the ETF Stock Exposure tool for EW

See insider activity

Frequently Asked Questions About EW

When does EW report earnings?

Edwards Lifesciences Corp (EW) is expected to report earnings on Feb 8, 2027.

Does EW pay dividends?

Edwards Lifesciences Corp (EW) does not currently pay a regular dividend.

What is EW's P/E ratio?

Edwards Lifesciences Corp has a price-to-earnings (P/E) ratio of 34.74.

What is EW's market cap?

Edwards Lifesciences Corp (EW) has a market capitalization of $58.11B with a current stock price of $102.14.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In